Home » Business, Health & Medicine, Pharmaceuticals & Biotech, UK » Chemotherapy Induced Peripheral Neuropathy: Latest Pipeline Review H2 2016 with Detail Drugs Profile
“Chemotherapy Introduced Peripheral Neuropathy Pipeline Review H2 2016”
‘Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2016’, covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. It develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Browse more detail information about Chemotherapy Induced Peripheral Neuropathy Pipeline Review H2 2016 at: http://www.absolutereports.com/chemotherapy-Induced-peripheral-neuropathy-pipeline-review-h2-2016-10315987

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

25 Key players in Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2016:

  • Amplyx Pharmaceuticals, Inc.
  • Can-Fite BioPharma Ltd.
  • DermaXon, LLC
  • Eisai Co., Ltd.
  • Immune Pharmaceuticals Inc.
  • INSYS Therapeutics, Inc.
  • KPI Therapeutics, Inc.
  • Krenitsky Pharmaceuticals Inc.

And 17 More Key Players

Get a PDF Sample of Chemotherapy Induced Peripheral Neuropathy Pipeline Review H2 2016 Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10315987

Drug Profiles of Included in Chemotherapy Induced Peripheral Neuropathy Pipeline Review H2 2016 Market Research Report:

  • (amitriptyline + ketamine hydrochloride)
  • AM-1710
  • AXPN-02
  • BR-297
  • Cannabidiol
  • Dimiracetam
  • Drugs for Peripheral Neuropathy
  • DX-0332
  • E-2072

And Other Drug Profiles

 Scope of Chemotherapy Induced Peripheral Neuropathy Pipeline Review H2 2016 Report-
– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
– The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

Get Discount on Chemotherapy Induced Peripheral Neuropathy Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10315987

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Media Contact
Company Name: Absolute Reports
Contact Person: Mr. Ameya Pingaley
Email: sales@absolutereports.com
Phone: +1 408 520 9750
Country: India
Website: http://www.absolutereports.com/chemotherapy-induced-peripheral-neuropathy-pipeline-review-h2-2016-10315987

Comments are closed.